SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more
BiotechTV - News
00:00
In vivo plans and targeted LNP delivery
John discusses next-step in vivo work, LNP de-targeting, Orbital partnership, and HSC targeting aspirations.
Play episode from 07:20
Transcript
